ArticleCurrent opinion in systems biology2017
Advances in bacterial cancer therapies using synthetic biology.
Article in Current opinion in systems biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia.Nature communications · 2024Trial
- Intratumoral microbiota in cancer immunotherapy: metabolic-epigenetic crosstalk and engineered bacterial therapeutics.Experimental hematology & oncology · 2026Review
- Deletion of themBio · 2026Article
- Bacteria as living biosensors for DNA.Nature reviews bioengineering · 2026Article
- Engineering the holobiont: Synthetic biology strategies for reversing bioenergetic collapse in radiation enteritis.AIMS microbiology · 2026Review
- Gastric bacterial microbiota and gastric carcinogenesis: from dysbiosis to immune remodeling and therapeutic opportunities.Frontiers in immunology · 2026Review
- Article
- Advanced adhesion and targeting strategies to prolong gut residence time and improve eLBP efficacy in colonic diseases.Advanced drug delivery reviews · 2025Review
- Anti-cancer effect of interleukin-2 fused to flagellin expressed by tumor-targeting Salmonella.Oncogene · 2025Article
- Leveraging dysregulated tumor metabolism for targeting anticancer bacteria.Science advances · 2025Article
- The emerging landscape of engineered bacteria cancer therapies.Nature biotechnology · 2025Article
- Engineered bacteria: Strategies and applications in cancer immunotherapy.Fundamental research · 2025Review
- Article
- Recent Advances in Spatiotemporal Manipulation of Engineered Bacteria for Precision Cancer Therapy.International journal of nanomedicine · 2025Review
- Microalgae: A Treasure Trove of Anticancer Nutraceuticals and Promising Therapeutic Mechanisms.Advanced biomedical research · 2025Review
- Synthetic biology approaches to enhance cancer immune responses.Frontiers in immunology · 2025Review
- What is the role of microbial biotechnology and genetic engineering in medicine?MicrobiologyOpen · 2024Review
- Bacterial therapies at the interface of synthetic biology and nanomedicine.Nature reviews bioengineering · 2024Article
- Advances in bacteria-based drug delivery systems for anti-tumor therapy.Clinical & translational immunology · 2024Review
- Enhancing photothermal therapy of tumors with image-guided thermal control of gene-expressing bacteria.Theranostics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Synthetic biology aims to apply engineering principles to biology by modulating the behavior of living organisms. An emerging application of this field is the engineering of bacteria as a cancer therapy by the programming of therapeutic, safety, and specificity features through genetic modification. Here, we review progress in this engineering including the targeting of bacteria to tumors, specific sensing and response to tumor microenvironments, remote induction methods, and controllable release of therapeutics. We discuss the most prominent bacteria strains used and their specific properties and the types of therapeutics tested thus far. Finally, we note current challenges, such as genetic stability, that researchers must address for successful clinical implementation of this novel therapy in humans.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.